indiafinancenews.com
Coronavirus India Live Updates: Supply of Covaxin to Centre at Rs 150 not sustainable in long run, says Bharat Biotech – The Indian Express
Bharat Biotech said that it has so far invested over Rs 500 crores at risk from its own resources for product development, clinical trials and setting up of manufacturing facilities for Covaxin.Cor…